Modality strategy in Eisai drug discovery: challenges toward next-generation therapeutics using proximity-inducing compound

计算机科学 模态(人机交互) 药品 医学 钥匙(锁) 医学物理学 系统工程 模式 制药技术 精密医学 梅德林 软件工程 组分(热力学) 药物开发
作者
Kazunobu Kira
出处
期刊:Folia Pharmacologica Japonica [Japanese Pharmacological Society]
卷期号:161 (3): 145-149
标识
DOI:10.1254/fpj.25095
摘要

In recent years, the concept of "modality" has attracted significant attention in drug discovery, encompassing diverse approaches such as small molecules, antibodies, nucleic acids, and cell-based therapies. Eisai has leveraged its long-standing expertise in small-molecule drug design to focus on proximity-inducing compound (PIC), which induces novel pharmacological effects by bringing two distinct proteins into close proximity. PIC form ternary complexes between a target protein and an effector protein, enabling mechanisms such as targeted degradation, post-translational modification, and modulation of protein-protein interactions. This strategy allows intervention in previously "undruggable" targets that lack suitable binding pockets for conventional inhibitors. Among PIC, targeted protein degraders such as proteolysis targeting chimera (PROTAC) and molecular glue degrader (MGD) have advanced rapidly into clinical development worldwide. Eisai's entry into this field was driven by the discovery of the unique mechanism of action of Indisulam and E7820, which function as MGD to degrade RBM39 via DCAF15 recruitment. Building on this foundation, Eisai is pursuing tumor-selective strategies, including the development of a CEACAM6-targeted degrader antibody conjugate (DAC) and PROTAC utilizing tumor-selective E3 ligases. These approaches aim to achieve both efficacy and safety by restricting degradation activity to cancer cells. PIC represent a transformative modality that expands the druggable proteome and offers new therapeutic options for intractable diseases. This article outlines Eisai's efforts in PIC-based drug discovery, with a focus on targeted protein degradation and future perspectives.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
lnx的应助被王哈哈哈哈哈哈哈采纳,获得30
1秒前
清晨的小鹿完成签到,获得积分10
1秒前
丘比特的应助被柠檬采纳,获得10
1秒前
1秒前
2秒前
恢恢发布了新的文献求助10
2秒前
你笑的样子真好看完成签到 ,获得积分10
2秒前
英俊的铭的应助被多情代双采纳,获得10
2秒前
伶俐安萱完成签到,获得积分10
2秒前
2秒前
33Rylee发布了新的文献求助10
3秒前
3秒前
花落云舒发布了新的文献求助10
3秒前
3秒前
宗友绿发布了新的文献求助10
3秒前
在水一方的应助被luca采纳,获得10
3秒前
4秒前
4秒前
聪明的破茧完成签到,获得积分10
4秒前
leungzzz完成签到,获得积分10
4秒前
江城闲鹤完成签到,获得积分10
4秒前
皮蛋发布了新的文献求助10
4秒前
爱科研的chen完成签到,获得积分10
4秒前
Nole的应助被sunny采纳,获得10
5秒前
Clarissa发布了新的文献求助20
5秒前
5秒前
6秒前
老迟到的可兰完成签到,获得积分10
6秒前
6秒前
6秒前
ParkMoonJ完成签到,获得积分10
6秒前
柒月半发布了新的文献求助10
7秒前
7秒前
一梦千年发布了新的文献求助10
7秒前
7秒前
初(*^▽^*)心的应助被李金玉采纳,获得10
7秒前
传奇3的应助被JChengTwo采纳,获得10
7秒前
hd完成签到,获得积分10
8秒前
1qq发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162918
求助须知:如何正确求助?哪些是违规求助? 9557210
关于积分的说明 21738626
捐赠科研通 7753447
什么是DOI,文献DOI怎么找? 3427983
关于科研通互助平台的介绍 2552768
邀请新用户注册赠送积分活动 2472619